Search

Search Constraints

You searched for: Author/Creator Verghese, Philip B.

Search Results

1. [O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE. (1st July 2017)

2. A randomized controlled study to evaluate the effect of bexarotene on amyloid‐β and apolipoprotein E metabolism in healthy subjects. Issue 2 (17th June 2016)

3. An examination of baseline plasma Aβ42/40 and intra‐individual cognitive variability (IICV) associations with longitudinal cognitive change in a Black Cohort: Data from the African Americans Fighting Alzheimer's in Midlife (AA‐FAIM) study. (20th December 2022)

5. Diabetes is related to cognition but not plasma amyloid‐β 42/40 in an African American cohort. (20th December 2022)

6. F4‐01‐01: PLASMA TEST FOR AMYLOID RISK SCREENING: THE C2N SPONSORED PARIS ADD‐ON STUDY TO IDEAS. (1st July 2019)

7. Plasma amyloid‐beta42/40 ratio as biomarker of cerebral amyloidosis in cognitively unimpaired APOE‐e4 homozygotes, heterozygotes and non‐carriers: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers. (7th December 2020)

8. Plasma Aβ42/40 and PET amyloid associations among late‐middle‐aged African Americans: Preliminary results from the AA‐FAIM study. (20th December 2022)

9. Plasma ratio of phospho‐ to non‐phospho‐tau at threonine 217 identifies brain amyloid burden as measured by quantitative amyloid PET in the PARIS sub‐study of IDEAS. (20th December 2022)

10. Trajectories of plasma Aβ42/40 among African Americans: Preliminary results from the African American Fighting Alzheimer's in Midlife (AA‐FAIM) study. (20th December 2022)